Patents by Inventor Jean Whaley

Jean Whaley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8883743
    Abstract: Methods are provided for treating obesity or causing weight loss in a mammalian subject or patient, wherein a therapeutically effective amount of an SGLT2 inhibitor alone or optionally in combination with another anti-obesity agent, is administered to a mammalian subject or patient. In addition, a pharmaceutical composition is provided which comprises an SGLT2 inhibitor, alone or in combination with another anti-obesity agent, and a pharmaceutically acceptable carrier thereof.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: November 11, 2014
    Assignee: AstraZeneca AB
    Inventors: William Washburn, Jean Whaley, Mario Maidonado, James F. List, Frederick T. Fiedorek
  • Publication number: 20120077739
    Abstract: Methods are provided for treating obesity or causing weight loss in a mammalian subject or patient, wherein a therapeutically effective amount of an SGLT2 inhibitor alone or optionally in combination with another anti-obesity agent, is administered to a mammalian subject or patient. In addition, a pharmaceutical composition is provided which comprises an SGLT2 inhibitor, alone or in combination with another anti-obesity agent, and a pharmaceutically acceptable carrier thereof.
    Type: Application
    Filed: December 2, 2011
    Publication date: March 29, 2012
    Applicant: BRISTOL-MYERS SQUIBB
    Inventors: William Washburn, Jean Whaley, Mario Maldonado, James F. List, Frederick T. Fiedorek
  • Patent number: 8088743
    Abstract: Methods are provided for treating obesity or causing weight loss in a mammalian subject or patient, wherein a therapeutically effective amount of an SGLT2 inhibitor alone or optionally in combination with another anti-obesity agent, is administered to a mammalian subject or patient. In addition, a pharmaceutical composition is provided which comprises an SGLT2 inhibitor, alone or in combination with another anti-obesity agent, and a pharmaceutically acceptable carrier thereof.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: January 3, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: William N. Washburn, Jean Whaley, Mario Maldonado, James F. List, Frederick T. Fiedorek
  • Publication number: 20080234367
    Abstract: Methods are provided for treating obesity or causing weight loss in a mammalian subject or patient, wherein a therapeutically effective amount of an SGLT2 inhibitor alone or optionally in combination with another anti-obesity agent, is administered to a mammalian subject or patient. In addition, a pharmaceutical composition is provided which comprises an SGLT2 inhibitor, alone or in combination with another anti-obesity agent, and a pharmaceutically acceptable carrier thereof.
    Type: Application
    Filed: March 21, 2008
    Publication date: September 25, 2008
    Applicant: BRISTOL-MYERS SQUIBB
    Inventors: William N. Washburn, Jean Whaley, Mario Maldonado, James F. List, Frederick T. Fiedorek
  • Publication number: 20050075358
    Abstract: Methods for treating cancer using IGF1R inhibitors in combination with insulin sensitizers are provided for the treatment or prevention of hyperglycemia.
    Type: Application
    Filed: October 5, 2004
    Publication date: April 7, 2005
    Inventors: Joan Carboni, Ricardo Attar, Marco Gottardis, Jean Whaley, Thomas Harrity